Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Regulus Therapeutics Inc. (RGLS)  
$2.21 0.04 (1.78%) as of 4:30 Fri 5/10


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 145,981,000
Market Cap: 322.62(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $1.13 - $2.88
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Regulus Therapeutics is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat diseases. Co.'s key product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. Co. has multiple programs in various stages of preclinical development including RGLS5579 as a clinical candidate in its glioblastoma multiforme program, its preclinical programs targeting the Hepatitis B virus and Non-Alcoholic Steatohepatitis program.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 0 25,516 25,516 25,516
Total Sell Value $0 $30,379 $30,379 $30,379
Total People Sold 0 3 3 3
Total Sell Transactions 0 3 3 3
End Date 2024-02-11 2023-11-10 2023-05-12 2022-05-12

   
Records found: 306
  Page 9 of 13  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Parshall B Lynne Director   –       •       •   2014-10-02 4 AS $6.64 $24,903 D/D (3,750) 6,934,250     -
   Alnylam Pharmaceuticals, Inc. 10% Owner   –       –       •   2014-10-01 4 AS $6.71 $21,808 D/D (3,250) 6,039,000     -
   Parshall B Lynne Director   –       •       •   2014-10-01 4 AS $6.71 $21,808 D/D (3,250) 6,938,000     -
   Xanthopoulos Kleanthis G President and CEO   •       •      –    2014-09-30 4 AS $7.02 $16,137 D/D (2,300) 2,466     -
   Xanthopoulos Kleanthis G President and CEO   •       •      –    2014-09-30 4 OE $0.38 $874 D/D 2,300 4,766     -
   Alnylam Pharmaceuticals, Inc. 10% Owner   –       –       •   2014-09-26 4 AS $7.04 $17,598 D/D (2,500) 6,042,250     -
   Parshall B Lynne Director   –       •       •   2014-09-26 4 AS $7.04 $17,598 D/D (2,500) 6,941,250     -
   Alnylam Pharmaceuticals, Inc. 10% Owner   –       –       •   2014-09-25 4 AS $7.12 $17,790 D/D (2,500) 6,044,750     -
   Parshall B Lynne Director   –       •       •   2014-09-25 4 AS $7.12 $17,790 D/D (2,500) 6,943,750     -
   Alnylam Pharmaceuticals, Inc. 10% Owner   –       –       •   2014-09-24 4 AS $7.19 $26,978 D/D (3,750) 6,047,250     -
   Parshall B Lynne Director   –       •       •   2014-09-24 4 AS $7.19 $26,978 D/D (3,750) 6,946,250     -
   Alnylam Pharmaceuticals, Inc. 10% Owner   –       –       •   2014-09-19 4 AS $7.22 $29,587 D/D (4,100) 6,051,000     -
   Parshall B Lynne Director   –       •       •   2014-09-19 4 AS $7.22 $29,587 D/D (4,100) 6,950,000     -
   Alnylam Pharmaceuticals, Inc. 10% Owner   –       –       •   2014-09-18 4 AS $7.40 $11,098 D/D (1,500) 6,055,100     -
   Parshall B Lynne Director   –       •       •   2014-09-18 4 AS $7.40 $11,098 D/D (1,500) 6,954,100     -
   Alnylam Pharmaceuticals, Inc. 10% Owner   –       –       •   2014-09-17 4 AS $7.43 $15,610 D/D (2,100) 6,056,600     -
   Parshall B Lynne Director   –       •       •   2014-09-17 4 AS $7.43 $15,610 D/D (2,100) 6,955,600     -
   Gibson Neil W Chief Scientific Officer   •       –      –    2014-09-12 4 AS $8.01 $17,617 D/D (2,200) 80,000     -
   Gibson Neil W Chief Scientific Officer   •       –      –    2014-09-12 4 OE $1.74 $3,828 D/D 2,200 82,200     -
   Alnylam Pharmaceuticals, Inc. 10% Owner   –       –       •   2014-09-12 4 AS $7.96 $27,861 D/D (3,500) 6,058,700     -
   Parshall B Lynne Director   –       •       •   2014-09-12 4 AS $7.96 $27,861 D/D (3,500) 6,957,700     -
   Gibson Neil W Chief Scientific Officer   •       –      –    2014-09-11 4 AS $8.01 $16,010 D/D (2,000) 80,000     -
   Gibson Neil W Chief Scientific Officer   •       –      –    2014-09-11 4 OE $1.74 $3,480 D/D 2,000 82,000     -
   Alnylam Pharmaceuticals, Inc. 10% Owner   –       –       •   2014-09-11 4 AS $7.83 $26,636 D/D (3,400) 6,062,200     -
   Parshall B Lynne Director   –       •       •   2014-09-11 4 AS $7.83 $26,636 D/D (3,400) 6,961,200     -
  306 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 9 of 13
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us